In 2019, sales of branded monoclonal antibody biologics in oncology exceeded $18 billion across the major markets (United States, EU5, and Japan), and the sales of biosimilars in these regions totaled $770 million. Throughout our 2019-2029 forecast period, increasing numbers of branded biologics are set to lose patent protection, with biosimilars expected to enter the market and eroding both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and region.

Table of contents

  • Biosimilars - Market Events And Forecast - Oncology
    • Market Forecast in the Major Pharmaceutical Markets
      • Major-Market Forecast: Oncology Monoclonal Antibodies
      • Terminology of Oncology Monoclonal Antibodies
        • Historical Performance of G-CSFs
          • G-CSF Sales in the United States: 2011-2018
          • G-CSF Sales in the EU5: 2008-2018
          • G-CSF Sales in Japan: 2015-2018
        • Terminology of G-CSFs
          • Major-Market Forecast: G-CSFs
      • Overarching Forecast Assumptions
        • Overview of Oncology MAb Brands in the Forecast
          • Biosimilar Entry Assumptions for MAbs in Oncology
        • Overview of Oncology MAb Biosimilars Assumptions
          • Overview of G-CSF Brands in the Forecast
            • Overview of Approved G-CSF Brands
            • Biosimilar Entry Assumptions for G-CSF Brands
          • Overview of Assumptions for Biosimilars of G-CSFs
            • United States
            • Europe
            • Japan
        • Drug-Specific Forecast Assumptions
          • Avastin
            • Outlook for Avastin
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Avastin Sales Forecast in the United States: 2019-2029
            • Avastin Sales Forecast in the EU5: 2019-2029
            • Avastin Sales Forecast in Japan: 2019-2029
          • Cyramza
            • Outlook for Cyramza
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Cyramza Sales Forecast in the United States: 2019-2029
            • Cyramza Sales Forecast in the EU5: 2019-2029
            • Cyramza Sales Forecast in Japan: 2019-2029
          • Erbitux
            • Outlook for Erbitux
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Erbitux Sales Forecast in the United States: 2019-2029
            • Erbitux Sales Forecast in the EU5: 2019-2029
            • Erbitux Sales Forecast in Japan: 2019-2029
          • Herceptin
            • Outlook for Herceptin
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Roche HER2-Franchise Defense Strategies
            • Herceptin Sales Forecast in the United States: 2019-2029
            • Herceptin Sales Forecast in the EU5: 2019-2029
            • Herceptin Sales Forecast in Japan: 2019-2029
          • Kadcyla
            • Outlook for Kadcyla
            • First Major-Market Biosimilar Entrants
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Kadcyla Sales Forecast in the United States: 2019-2029
            • Kadcyla Sales Forecast in the EU5: 2019-2029
            • Kadcyla Sales Forecast in Japan: 2019-2029
          • Perjeta
            • Outlook for Perjeta
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Perjeta Sales Forecast in the United States: 2019-2029
            • Perjeta Sales Forecast in the EU5: 2019-2029
            • Perjeta Sales Forecast in Japan: 2019-2029
          • Rituxan / MabThera
            • Outlook for Rituxan / MabThera
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Roche CD20-Franchise Defense Strategies
            • Rituxan Sales Forecast in Oncology for the United States: 2019-2029
            • MabThera Sales Forecast in Oncology for the EU5: 2019-2029
            • Rituxan Sales Forecast in Oncology for Japan: 2019-2029
            • Rituxan Sales Forecast for the United States (Immunology and Oncology): 2019-2029
            • MabThera Sales Forecast for the EU5 (Immunology and Oncology): 2019-2029
          • Vectibix
            • Outlook for Vectibix
            • First Major-Market Biosimilar Entrants
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Vectibix Sales Forecast in the United States: 2019-2029
            • Vectibix Sales Forecast in the EU5: 2019-2029
            • Vectibix Sales Forecast in Japan: 2019-2029
          • Yervoy
            • Outlook for Yervoy
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Yervoy Sales Forecast in the United States: 2019-2029
            • Yervoy Sales Forecast in the EU5: 2019-2029
            • Yervoy Sales Forecast in Japan: 2019-2029
          • Neupogen / Gran
            • Outlook for Neupogen / Gran
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilars Uptake Assumptions
            • Neupogen Sales Forecast in the United States: 2018-2028
            • Neupogen Sales Forecast in the EU5: 2018-2028
            • Gran Sales Forecast in Japan: 2018-2028
            • Brand and Biosimilar Market Forecast and Assumptions for Neupogen / Gran: 2018-2028
          • Neulasta / G-Lasta
            • Outlook for Neulasta
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Net Cost Assumptions
            • Neulasta Sales Forecast in the United States: 2018-2028
            • Neulasta Sales Forecast in the EU5: 2018-2028
            • G-Lasta Sales Forecast in Japan: 2018-2028
            • Brand and Biosimilar Market Forecast and Assumptions for Neulasta / G-Lasta: 2018-2028

      Author(s): Hamzah Aideed, M.Sc.; Yashu Malhotra

      Hamzah Aideed, M.Sc., is a principal analyst on the Biosimilars team at DRG, part of Clarivate. He conducts primary and secondary market research to provide in-depth analysis and insight into the biopharmaceutical industry. Prior to joining DRG, Mr. Aideed was a senior research executive in consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies for bespoke ad-hoc consulting projects. He holds an M.Sc. in biotechnology, bioprocessing, and business management from the University of Warwick and a B.Sc. in biological chemistry from Aston University in Birmingham.

      Yashu Malhotra, M.Sc., is an associate analyst on the Biosimilars and Onkos teams at DRG, part of Clarivate. Prior to joining DRG, she was a senior analyst in the life sciences at Course5 Intelligence. She also worked in competitive intelligence at WNS Global Services. Ms. Malhotra earned her master’s degree in pharmacy (quality assurance) from India’s Delhi Institute of Pharmaceutical Sciences and Research.


      Related Reports

      Biomarkers In Oncology - Access & Reimbursement - Detailed, Expanded Analysis (US) Biomarkers In Oncology

      Biomarkers have become an integral component of the treatment landscape for an increasing number of oncology indications. Patients’ biomarker status often directs prescription choice in malig...

      View Details

      Biosimilars - Geographic Focus: China - Biosimilars | China In-Depth | Oncology And Immunology | China

      The approval of Shanghai Henlius Biotech's HLX01—a biosimilar of Roche's Rituxan (rituximab)—in February 2019 marked the beginning of the biosimilars era in China. Since then, b...

      View Details

      Biosimilars - Emerging Biosimilars - Special Topics: Oncology Biosimilars In The United States - Wave 2

      Biosimilars referencing Roche/Genentech’s portfolio of blockbuster oncology monoclonal antibodies—Avastin, Herceptin, and Rituxan—launched in the United States throughout the seco...

      View Details

      Biosimilars - Current Treatment - Oncology

      In 2019, Amgen / Allergan's trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launch...

      View Details